BCL2: A promising cancer therapeutic target

Radha, Gudapureddy and Raghavan, Sathees C (2017) BCL2: A promising cancer therapeutic target. In: BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1868 (1). pp. 309-314.

PDF Bio_Bio_Act_Rev_Can_1868-1_309_2017.pdf - Published Version Restricted to Registered users only Download (837kB) | Request a copy

Abstract

A remarkable characteristic of majority of cancer cells is that, they fail to undergo apoptosis, which in turn confers them a survival advantage over normal cells. Targeted cancer therapy aims at disrupting the functions of proteins that play an important role during cancer progression. Antiapoptotic protein, BCL2, is one such protein that is highly upregulated in many cancers as compared to normal cells, making it an ideal target for cancer therapy. Although, several BCL2 targeting agents have been investigated over the past 30 years, very few have exhibited any clinical significance. This mini-review outlines a road map of existing BCL2 inhibitors and their relevance in treating cancer, and discusses potential strategies for future research with respect to BCL2 specific cancer therapy.

Item Type:	Editorials/Short Communications
Publication:	BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Additional Information:	Copy right for this article belongs to the ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
Department/Centre:	Division of Biological Sciences > Biochemistry
Date Deposited:	23 Sep 2017 05:04
Last Modified:	04 Oct 2018 15:00
URI:	http://eprints.iisc.ac.in/id/eprint/57875

Actions (login required)

View Item